The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 CongressPRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. “In a precli ...

近日，在今年的彭博科技峰会上，Perplexity联合创始人兼 Arvind Srinivas在与彭博的访谈中发表了对搜 索入口类大模型产品竞争能力的看法。 Perplexity为一家专注于AI搜索引擎应用的初创公司。据《金融时报》消息，Perplexity正在进行新一轮5 亿美元融资谈判，最新估值近140亿美元。今年2月，公司宣布计划推出融合AI智能体功能的浏览器 Comet，Comet的beta版本于5月正式上线。 4月，Perplexity与摩托罗拉正式签约，将在摩托罗拉手机上预装其AI助手Perplexity Assistant。另据 CNBC近日报道，Perplexity将与三星达成协议，计划将其AI助手集成到S26手机中，成为三星手机的默 认设置产品。苹果副总裁近期也开始与Perplexity进行商业接洽。与手机硬件商的合作，将大幅加快 Perplexity的模型训练、规模化部署和变现的速度。 此前，Arvind在CNBC采访中表示："在大模型搜索引擎中，Perplexity能提供目前最便宜的API，而且准 确度也最高，高于谷歌和OpenAI。不过，我认为AI问答服务最终将变成一种商品（commo ...

Financial Data and Key Metrics Changes - The company positions itself as a "Search AI company," focusing on providing high-performance solutions for storing, searching, and analyzing vast amounts of data [5][6] - The core technology is centered around Elasticsearch, which serves as the primary data storage and processing engine [8] Business Line Data and Key Metrics Changes - The company markets its offerings in three main areas: developer tools, observability products, and security solutions [9][12] - The observability product combines unstructured log messages with structured metrics and traces to identify operational issues [10] - The security product is described as a modern SIEM that goes beyond traditional capabilities, addressing the increasing complexity of security threats [11][49] Market Data and Key Metrics Changes - The company has seen a diverse range of use cases for Elasticsearch, from traditional search applications to more complex scenarios like transaction tracking and logistics [15][19] - The advent of AI has expanded the potential applications of Elasticsearch, with a focus on semantic and vector search capabilities [21][25] Company Strategy and Development Direction - The company aims to simplify the developer experience by providing out-of-the-box tools for building generative AI applications [36][37] - There is a strong emphasis on integrating AI capabilities into their products, including features like vector search and semantic search to enhance search relevance [25][26] - The acquisition of Keep Alerting is seen as a strategic move to enhance workflow automation capabilities in both security and observability [64][66] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that customers are at various stages of maturity in adopting generative AI applications, with some already in production while others are still experimenting [39][40] - The importance of providing accurate and contextually relevant information is highlighted as critical for the success of AI applications [72][75] Other Important Information - The company has established partnerships with major AI model providers to enhance its offerings and ensure compatibility with various AI frameworks [32][68] - The focus on security is underscored by the need for per-user and per-document security measures, which are critical for enterprise applications [80][81] Q&A Session Summary Question: What is Elastic's overall strategy regarding AI? - The company is focused on building core components for developers while also utilizing these components in their observability and security solutions [23][24] Question: Are customers still in the experimental stage with generative AI applications? - Customers are at different maturity levels, with some already deploying generative AI applications in production [39][40] Question: How does Elastic position itself in the security space? - The company provides a comprehensive security suite, including a modern SIEM with prebuilt detection rules and AI-powered features [46][49] Question: What is the integration with NVIDIA's enterprise AI factory about? - The partnership aims to leverage NVIDIA's capabilities for running AI workloads, enhancing the company's offerings in the AI space [90]

[Music] Bringing a life-saving drug to market requires analyzing massive amounts of complex data. The pharmaceutical industry needs a faster, more automated way to extract meaning and act on it. Ivia is using Agentic AI to do exactly that.Training AI agents to navigate more than a million data streams for clinical, medical, and commercial professionals. Its healthcare grade AI platform combines a growing set of AI agents, each designed to streamline how insights turn into action. Built with NVIDIA Neotron m ...

AI agents are digital assistants based on a prompt. They reason through and break down problems into multi-step plans. They use the proper tools, work with other agents, and use context from memory to properly execute the job on NVIDIA accelerated systems.It starts with a simple prompt. Let's ask Perplexity to help start a food truck in Paris. First, the perplexity agent reasons through the prompt and forms a plan.Then calls other agents to help tackle each step using many tools. The market researcher reads ...

教育部网站6月11日发布《关于拟同意设置本科高等学校的公示》。其中包括"设立大湾区大学"。 据大湾区大学（筹）官网介绍，筹建大湾区大学是贯彻落实《粤港澳大湾区发展规划纲要》的重大战略 举措。大湾区大学是由广东省人民政府举办、东莞市政府投入保障为主的公办普通高等学校。学校立足 粤港澳大湾区，面向全中国，辐射全世界，以理工为主、精理强工，致力于办成一所"国际水准、开放 包容、湾区特色"，能引领未来科技发展、产业升级和社会进步的新型研究型大学。 学校开展全日制本科和研究生教育，形成本硕博贯通式培养体系，预计2030年达到在校生10000人左 右，本科生与研究生规模比例预计达1：1左右。 在学生培养方面，针对本科生，首批设置数学与应用数学、物理学、计算机科学与技术、材料科学与工 程和工业工程等5个本科专业，实行大类招生，分类培养，并对理学和工学等学科门类制定差异化的人 才培养方案。 松山湖校区主要建设与综合性国家科学中心有关的大科学装置、新型研发机构融合办学的学科领域，设 立相关领域研究院和科研平台，同时满足办学初期需求。 滨海湾校区同步启动，主要满足本科生和研究生培养、产学研合作和国际合作、创新创业孵化以及行政 办 ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.I initiated my coverage on Credo Technology Group Holding Ltd (NASDAQ: CRDO ) with a bullish rating in January 2025 , arguing that the CRDO stock's valuation — despite seemingly high multiples — isn't as expensive as many might haveHe leads the inves ...

Summary of PTC Therapeutics Conference Call Company Overview - **Company**: PTC Therapeutics - **Sector**: Biotechnology - **Key Executives**: Matt Klein (CEO), Pierre Grave (CFO) Key Points Industry and Company Performance - PTC Therapeutics is experiencing a pivotal year with strong execution across all areas of the company, following a successful 2024 [2][3] - The company has submitted four FDA New Drug Applications (NDAs), with one approval received and three pending, including the Suppiance NDA expected to be approved within six weeks [3] Financial Position - As of Q1, PTC Therapeutics has over $2 billion in cash, providing a solid foundation for planned product launches and R&D advancements [3] Product Pipeline and Launches - Upcoming products include Suppiance for PKU and potential approvals for Friedreich ataxia and Translarna in the U.S. [3][4] - The company is preparing for the launch of Suppiance in Europe, with an early access program already initiated in Germany [23][24] Translarna in Europe - Despite the lack of marketing authorization renewal, over half of European countries wish to continue commercializing Translarna, allowing PTC to maintain 25-30% of European revenue, which is about 40% of overall Translarna revenue for 2024 [7][8][10] Market Opportunity for Suppiance - Suppiance is positioned as a highly differentiated therapy for PKU, addressing a significant unmet need as only 10-15% of the estimated 15,000-17,000 patients in the U.S. are currently on existing therapies [12][13] - The company plans to price Suppiance at a premium to existing therapies, with payer support anticipated [13][14] Commercial Strategy - PTC has a well-established commercial team experienced in rare disease therapies, which will facilitate the launch of Suppiance [14] - The company has identified 103 PKU expert centers in the U.S., many of which overlap with existing treatment centers, aiding in the transition to new therapies [17][18] Friedreich Ataxia Program - Vatiquinone is positioned as a therapy for both pediatric and adult patients, with a significant market opportunity due to its safety and tolerability profile [39][40] - The company expects to target pediatric patients first, followed by adults who may have had issues with existing therapies [41][42] Regulatory and Clinical Development - The PDUFA date for vatiquinone is August 19, with positive feedback from the FDA regarding the absence of an AdCom meeting [49] - PTC518 for Huntington's disease has shown promising Phase II results, with plans for accelerated approval discussions based on the data [51][55] Cash Management and Future Plans - PTC Therapeutics has a strong cash position, allowing for flexibility in internal development and potential business development activities [66][67] - The company aims to reach $2 billion in top-line revenue, with significant contributions expected from PKU and Friedreich ataxia products [67][68] Conclusion - PTC Therapeutics is well-positioned for growth with a robust pipeline, strong financials, and a strategic approach to market entry and commercialization across its product offerings. The company is focused on addressing unmet needs in rare diseases while maintaining a solid cash position to support its initiatives.

Project Overview - The Galileo Project is a scientific endeavor aimed at exploring the possibility of extraterrestrial life, distinct from government investigations driven by national security concerns [5][30] - The project utilizes artificial intelligence to scan the sky for UAP, sharing all findings openly [1] - The project has established the first Galileo observatory, testing instruments with plans for hundreds of copies in multiple locations [7] Technology and Methodology - The project employs a network of cameras and specialized sensors recording the entire sky 24/7 [7] - AI software is built from scratch to filter out known objects and identify anomalies [8] - Instrumentation monitors the entire electromagnetic spectrum, focusing on objects within the atmosphere [18] - Over five months, approximately half a million objects were collected and reconstructed with a 95% confidence level [24] UAP and National Security - The US government released a report confirming over 140 sightings of unidentified aerial phenomena in 2021 [3] - Congress has elevated UAP to a top national security concern, with sightings being routine but under-reported [26] - The US Department of Defense announced the Gremlin Project, similar to The Galileo Project but closed source [28] Scientific and Academic Perspective - The Galileo Project seeks to bring scientific rigor to UAP research, challenging the stigma and promoting open investigation [14][25] - The project is open source, publishing all findings in peer-reviewed papers [29][30]

论文第一作者为何浩然，香港科技大学二年级博士，他的研究方向包括强化学习、生成流模型（GFlowNets）以及具身智能，通讯作者为香港科技大学电子与计算 机工程系、计算机科学与工程系助理教授潘玲。 测试时扩展（Test-Time Scaling）极大提升了大语言模型的性能，涌现出了如 OpenAI o 系列模型和 DeepSeek R1 等众多爆款。那么，什么是视觉领域的 test-time scaling？又该如何定义？ 为了回答这一问题，最近 香港科技大学 联合 快手可灵团队 推出 Evolutionary Search （EvoSearch） 方法，通过提高推理时的计算量来大幅提升模型的生成质 量，支持图像和视频生成，支持目前最先进的 diffusion-based 和 flow-based 模型。EvoSearch 无需训练，无需梯度更新，即可在一系列任务上取得显著最优效果， 并且表现出良好的 scaling up 能力、鲁棒性和泛化性。 随着测试时计算量提升，EvoSearch 表明 SD2.1 和 Flux.1-dev 也有潜力媲美甚至超过 GPT4o。对于视频生成，Wan 1.3B 也能超过 Wa ...